Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.

Grab AL, Seckinger A, Horn P, Hose D, Cavalcanti-Adam EA.

Acta Biomater. 2019 Jul 11. pii: S1742-7061(19)30498-2. doi: 10.1016/j.actbio.2019.07.018. [Epub ahead of print]

PMID:
31302300
2.

Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cells.

Darche FF, Rivinius R, Köllensperger E, Leimer U, Germann G, Seckinger A, Hose D, Schröter J, Bruehl C, Draguhn A, Gabriel R, Schmidt M, Koenen M, Thomas D, Katus HA, Schweizer PA.

Life Sci. 2019 Sep 1;232:116620. doi: 10.1016/j.lfs.2019.116620. Epub 2019 Jul 7.

PMID:
31291594
3.

Kinome expression profiling to target new therapeutic avenues in multiple myeloma.

de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J.

Haematologica. 2019 Jul 9. pii: haematol.2018.208306. doi: 10.3324/haematol.2018.208306. [Epub ahead of print]

4.

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.

5.

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.

Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI.

Blood. 2019 Jul 4;134(1):30-43. doi: 10.1182/blood.2018880930. Epub 2019 Apr 25.

PMID:
31023703
6.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Haenel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H.

Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8. No abstract available.

7.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.

8.

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Requirand G, Robert N, Boireau S, Vincent L, Seckinger A, Bouhya S, Ceballos P, Cartron G, Hose D, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2019 May;96(3):209-214. doi: 10.1002/cyto.b.21730. Epub 2018 Nov 12.

PMID:
30417559
9.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

10.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.

11.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.

12.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Dec;32(12):2717-2719. doi: 10.1038/s41375-018-0202-1. Epub 2018 Jul 6. No abstract available.

PMID:
29977018
13.

RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine.

Seckinger A, Bähr-Ivacevic T, Benes V, Hose D.

Methods Mol Biol. 2018;1792:97-115. doi: 10.1007/978-1-4939-7865-6_7.

PMID:
29797254
14.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.

JCI Insight. 2018 Apr 19;3(8). pii: 98259. doi: 10.1172/jci.insight.98259. eCollection 2018 Apr 19.

15.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Sep;94(5):611-620. doi: 10.1002/cyto.b.21636. Epub 2018 Apr 20.

PMID:
29577600
16.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

17.

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S.

Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0. No abstract available.

18.

Quantification of plasma cell dynamics using mathematical modelling.

Mohr M, Hose D, Seckinger A, Marciniak-Czochra A.

R Soc Open Sci. 2018 Jan 24;5(1):170759. doi: 10.1098/rsos.170759. eCollection 2018 Jan.

19.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

20.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.

21.

From Bench to Bedside: A View on Bioinformatics Pipelines.

Flores B, Hose D, Seckinger A, Knaup P, Ganzinger M.

Stud Health Technol Inform. 2017;245:375-378.

PMID:
29295119
22.

A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model.

Schulze F, Malhan D, El Khassawna T, Heiss C, Seckinger A, Hose D, Rösen-Wolff A.

BMC Genomics. 2017 Dec 19;18(1):975. doi: 10.1186/s12864-017-4356-4.

23.

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, Boireau S, Seckinger A, Hose D, Klein B, Moreaux J.

Oncotarget. 2017 Oct 30;8(58):98931-98944. doi: 10.18632/oncotarget.22131. eCollection 2017 Nov 17.

24.

Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions.

Clemens J, Welti L, Schäfer J, Seckinger A, Burhenne J, Theile D, Weiss J.

Oncol Lett. 2017 Sep;14(3):3185-3192. doi: 10.3892/ol.2017.6560. Epub 2017 Jul 8.

25.

Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.

Kruppke B, Hose D, Schnettler R, Seckinger A, Rößler S, Hanke T, Heinemann S.

J Biomed Mater Res B Appl Biomater. 2018 Apr;106(3):1165-1173. doi: 10.1002/jbm.b.33931. Epub 2017 May 29.

PMID:
28556562
26.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

27.

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.

Schäfer J, Welti L, Seckinger A, Burhenne J, Theile D, Weiss J.

Cancer Chemother Pharmacol. 2017 Jul;80(1):71-79. doi: 10.1007/s00280-017-3335-4. Epub 2017 May 12.

PMID:
28500557
28.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.

29.

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, Hemminki K, Goldschmidt H, Schönland SO, Jauch A.

Haematologica. 2017 Jul;102(7):1281-1290. doi: 10.3324/haematol.2016.160721. Epub 2017 Mar 24.

30.

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD.

Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.

31.

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.

Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, Tiers L, Bruyer A, Vincent L, Grandmougin C, Seckinger A, Goldschmidt H, Constantinou A, Pasero P, Hose D, Moreaux J.

Leukemia. 2017 Oct;31(10):2104-2113. doi: 10.1038/leu.2017.54. Epub 2017 Feb 10.

32.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K.

Leukemia. 2017 Jul;31(7):1570-1581. doi: 10.1038/leu.2016.358. Epub 2016 Nov 28.

PMID:
27890927
33.

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.

Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.

34.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

35.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17.

36.

Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.

Dettmer S, Theile D, Schäfer J, Seckinger A, Burhenne J, Weiss J.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Oct;389(10):1091-101. doi: 10.1007/s00210-016-1276-9. Epub 2016 Jul 15.

PMID:
27422413
37.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

38.

Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage.

Schoenhals M, Jourdan M, Seckinger A, Pantesco V, Hose D, Kassambara A, Moreaux J, Klein B.

Cell Cycle. 2016 Jul 17;15(14):1919-28. doi: 10.1080/15384101.2016.1191709. Epub 2016 May 26.

39.

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma.

Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J.

Br J Cancer. 2016 Mar 1;114(5):519-23. doi: 10.1038/bjc.2016.20. Epub 2016 Feb 11.

40.

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.

Meißner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M, Duering J, Salwender H, Goldschmidt H, Morgan GJ, Hose D, Weinhold N.

BMC Med Genomics. 2015 Dec 30;8:85. doi: 10.1186/s12920-015-0161-6.

41.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A.

Haematologica. 2016 Mar;101(3):e116-9. doi: 10.3324/haematol.2015.136929. Epub 2015 Nov 26. No abstract available.

42.

miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.

Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D.

Oncotarget. 2015 Nov 17;6(36):39165-83. doi: 10.18632/oncotarget.5381.

43.

Regulation of integrin and growth factor signaling in biomaterials for osteodifferentiation.

Wei Q, Pohl TL, Seckinger A, Spatz JP, Cavalcanti-Adam EA.

Beilstein J Org Chem. 2015 May 13;11:773-83. doi: 10.3762/bjoc.11.87. eCollection 2015. Review.

44.

Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions.

Striegler C, Schumacher M, Effenberg C, Müller M, Seckinger A, Schnettler R, Voit B, Hose D, Gelinsky M, Appelhans D.

Macromol Biosci. 2015 Sep;15(9):1283-95. doi: 10.1002/mabi.201500085. Epub 2015 May 28.

PMID:
26018141
45.

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma.

Cowan G, Weston-Bell NJ, Bryant D, Seckinger A, Hose D, Zojer N, Sahota SS.

Oncotarget. 2015 May 30;6(15):13229-40.

46.

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Bolomsky A, Hose D, Schreder M, Seckinger A, Lipp S, Klein B, Heintel D, Ludwig H, Zojer N.

J Hematol Oncol. 2015 Feb 8;8:10. doi: 10.1186/s13045-014-0105-1.

47.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.

48.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
49.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559
50.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L, Cartron G, Moreaux J, Hose D, Klein B.

Oncotarget. 2015 Mar 20;6(8):6431-47.

Supplemental Content

Loading ...
Support Center